Letaplimab represents a novel clinical strategy for addressing complement-mediated illnesses. This biologic targets C1q, a essential molecule of the complement pathway, aiming to inhibit its initial triggering. https://lewisggwv501058.blog-gold.com/58588656/letaplimab-a-innovative-medical-method